Table 1.

Autologous stem cell transplantation versus conventional chemotherapy. Results of randomized trials.

Study(reference)No. ofPatientsAgeCR Rate(%)(CC vs ASCT)p valueMedian EFS(months)(CC vs ASCT)p valueMedian OS(months)(CC vs ASCT)p value
Abbreviations: ASCT, autologous stem cell transplantation; CC, conventional chemotherapy; IFM, Intergroupe Francophone du Myelome; MRC, Medical Research Council; MAG, Myelome Auto Greffe; PETHEMA, Spanish Cooperative Group; USIG, US Inter Group; IMMSG, Italian Multiple Myeloma Study Group; CR, complete remission; EFS, event-free survival; NS, not significant 
IFM90 (1) 200 ≤ 65 5 vs 22 < 0.001 18 vs 28 0.01 44 vs 57 0.03 
MRC7 (2) 401 ≤ 64 8 vs 44 < 0.001 19 vs 31 < 0.001 42 vs 54 < 0.001 
MAG91 (3) 190 55–65   19 vs 25 0.05 45 vs 42 NS 
PETHEMA (4) 164 ≤ 65 11 vs 30 0.002 34 vs 42 NS 67 vs 65 NS 
USIG (6) 50  15 vs 17 NS 21 vs 25 0.05 53 vs 58 NS 
IMMSG (5) 195 50–70 7 vs 26 < 0.0001 16 vs 28 0.0036 43 vs 58+ 0.0008 
Study(reference)No. ofPatientsAgeCR Rate(%)(CC vs ASCT)p valueMedian EFS(months)(CC vs ASCT)p valueMedian OS(months)(CC vs ASCT)p value
Abbreviations: ASCT, autologous stem cell transplantation; CC, conventional chemotherapy; IFM, Intergroupe Francophone du Myelome; MRC, Medical Research Council; MAG, Myelome Auto Greffe; PETHEMA, Spanish Cooperative Group; USIG, US Inter Group; IMMSG, Italian Multiple Myeloma Study Group; CR, complete remission; EFS, event-free survival; NS, not significant 
IFM90 (1) 200 ≤ 65 5 vs 22 < 0.001 18 vs 28 0.01 44 vs 57 0.03 
MRC7 (2) 401 ≤ 64 8 vs 44 < 0.001 19 vs 31 < 0.001 42 vs 54 < 0.001 
MAG91 (3) 190 55–65   19 vs 25 0.05 45 vs 42 NS 
PETHEMA (4) 164 ≤ 65 11 vs 30 0.002 34 vs 42 NS 67 vs 65 NS 
USIG (6) 50  15 vs 17 NS 21 vs 25 0.05 53 vs 58 NS 
IMMSG (5) 195 50–70 7 vs 26 < 0.0001 16 vs 28 0.0036 43 vs 58+ 0.0008 

or Create an Account

Close Modal
Close Modal